Biocept to Participate in Three Virtual Investment Conferences in March
Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS)
Provides update on COVID-19 testing with more than 300,000 samples received
H.C. Wainwright Global Life Sciences Virtual Conferencebeing held March 9-10, 2021. Bioceptwill hold virtual investor meetings. Investors can request a meeting by registering for the H.C. Wainwright Global Life Sciences Virtual Conferencehere.
Roth Conferencebeing held March 15-17, 2021. Bioceptwill hold virtual investor meetings. Investors interested in arranging a virtual meeting should contact their Roth Capital Partnerssales representative or LHA Investor Relations. A webcast of Biocept’s presentation has been pre-recorded and is available on the Company’s website here. Roth Conferenceinformation is available here.
Emerging Growth Virtual Conferencebeing held March 17-19, 2021. Bioceptwill participate in a fireside chat hosted by Maxim GroupSenior Managing Director Jason McCarthy, Ph.D. on Friday, March 19at 1:30 p.m. Eastern time. Investors can register for the conference here.
Biocept’s corporate presentation is available on the Company’s website here.
“Our presentations highlight progress with our neuro-oncology initiative and strategy to become the standard of care when diagnosing and monitoring the spread of cancer into the CNS,” said
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our ability to become standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the CNS, our ability to expand our RT-PCR COVID-19 testing portfolio under our recently announced supply agreement with Aegea Biotechnologies, and the ability of Biocept’s liquid biopsy technology to provide physicians with clinically actionable information, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including the risk that our products and services may not perform as expected. These and other risks are described in greater detail under the "Risk Factors" heading of our Quarterly Report on Form 10-Q for the quarter ended
LHA Investor Relations